Patent · US Active

C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity

US8846647B2 · kind B2 · utility

7Cited by

5References

16Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Alicia Regueiro-Ren · Wallingford, US
Zheng Liu · Beacon Falls, US
Jacob Swidorski · Wallingford, US
Ny Sin · East Hampton, US
Brian Lee Venables · Durham, US
Sing-Yuen Sit · Meriden, US
Yan Chen · Foster City, US
Jie Chen · Houston, US
Nicholas A. Meanwell · East Hampton, US

Key dates

Filing date	Jan 27, 2012
Grant date	Sep 30, 2014
Priority date	—
Expiry date	Dec 9, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07J63/008
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III:These compounds are useful for the treatment of HIV and AIDS.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.